Daily Archives: September 2, 2019
Mon September 2 – 10 Stories of The Day!
2 Sep, 2019 | 01:22h | UTC
News Release: Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes (free)
6 – Maximum-fixed energy shocks for cardioverting atrial fibrillation – European Heart Journal (free)
Commentary: Comparison of High vs. Escalating Shocks – CHESS – American College of Cardiology (free)
7 – Complete Revascularization with Multivessel PCI for Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Complete Versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease After Early PCI for STEMI – COMPLETE – American College of Cardiology (free) AND Complete revascularisation is superior to culprit-lesion only intervention – European Society of Cardiology (free)
Related Cochrane Review: Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease – Cochrane Library (free)
Related Meta-analysis: Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials – JACC: Cardiovascular Interventions (free)
8 – Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction – DAPA-HF – American College of Cardiology (free) Dapagliflozin reduces death and hospitalisation in patients with heart failure – European Society of Cardiology (free)
9 – HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin – TCTMD (free) AND Risk-Based Thresholds for hs-Troponin I Safely Speed MI Rule-Out – MedPage Today (free registration required) AND HISTORIC: Early Rule-Out Strategy Using High-Sensitivity Cardiac Troponin I Reduced Length of Stay, Hospital Readmissions in Suspected ACS Patients – American College of Cardiology (free)
Related Studies: Randomized Trial: High-Sensitivity Troponin in the Evaluation of Suspected Acute Coronary Syndrome (free study and commentaries) AND Cohort Study: The Introduction of High-sensitive Troponins Had No Impact on Survival (free study and commentaries)
#ESCCongress – 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes
2 Sep, 2019 | 01:20h | UTCNews Release: Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes (free)
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for Chronic Coronary Syndromes – what's new? what has changed? what are the 2019 new major recommendations? https://t.co/wPPZCYdRfH
@escardio #ESCCongress #ESCCoT #cardiotwitter pic.twitter.com/RBhIKgV9Uq
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism
2 Sep, 2019 | 01:19h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for Acute Pulmonary Embolism – what's new? what has changed? what are the main 2019 recommendations? https://t.co/nyLf7eWk5G@escardio #ESCcongress #ESCCoT #cardiotwitter pic.twitter.com/DEFBMKdwcO
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia
2 Sep, 2019 | 01:17h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for the management of Supraventricular Tachycardia – what's new? what has changed? what are the main 2019 recommendations? https://t.co/A3Y15T3Dy8#ESCcongress #cardiotwitter pic.twitter.com/GVkMoOvYQQ
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
2 Sep, 2019 | 01:15h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for the management of Dyslipidaemias – what's new? what has changed? what are the main 2019 recommendations? https://t.co/aBU1PkGc2k
@escardio #ESCCongress #ESCCoT #cardiotwitter pic.twitter.com/NChfhPNXDq
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – [Abstract Only] Randomized Trial: Complete Revascularization Superior to Culprit-lesion-only PCI in Patients with ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Coronary Artery Disease
2 Sep, 2019 | 01:11h | UTCComplete Revascularization with Multivessel PCI for Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Complete Versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease After Early PCI for STEMI – COMPLETE – American College of Cardiology (free) AND Complete revascularisation is superior to culprit-lesion only intervention – European Society of Cardiology (free)
Related Cochrane Review: Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease – Cochrane Library (free)
Related Meta-analysis: Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials – JACC: Cardiovascular Interventions (free)
Related Commentary on Twitter
#COMPLETE trial results out at #ESCCongress! Complete revascularisation of multivessel coronary disease after STEMI superior to culprit-only PCI. Reduction in composite of CV death/MI from 10.5% to 7.8% at 3yrs – driven by lwr incidence of MI. https://t.co/STBfNuGzDY pic.twitter.com/VNsaQArG0x
— Tom Cahill (@tomjcahill) September 1, 2019
#ESCCongress – 2019 ESC Guidelines on Diabetes, Pre-diabetes, and Cardiovascular Diseases
2 Sep, 2019 | 01:14h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESGuidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases – what's new? what has changed? what are the main 2019 recommendations? https://t.co/FY6xt34jNo#ESCCongress #cardiotwitter pic.twitter.com/q1HBPfRO5f
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – Randomized Trial Suggests Maximum-fixed Energy Shocks (360-360-360 J) are More Effective for Cardioverting Atrial Fibrillation
2 Sep, 2019 | 01:12h | UTCMaximum-fixed energy shocks for cardioverting atrial fibrillation – European Heart Journal (free)
Commentary: Comparison of High vs. Escalating Shocks – CHESS – American College of Cardiology (free)
Related Commentary on Twitter
Maximum-fixed energy shocks (360-360-360J) were more effective and equally safe when compared with low-escalating energy shocks (125-150-200J) for cardioverting atrial fibrillation https://t.co/RkYCNILvck
@escardio @TomLuscher #EHJ #ESCcongress #freeaccess pic.twitter.com/3ZxS5Xx2Ok
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2019
#ESCCongress – [Not Published Yet] Randomized Trial Supports Single High-sensitive Troponin Measurement to Rule out Myocardial Infarction
2 Sep, 2019 | 01:06h | UTCCommentaries: HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin – TCTMD (free) AND Risk-Based Thresholds for hs-Troponin I Safely Speed MI Rule-Out – MedPage Today (free registration required) AND HISTORIC: Early Rule-Out Strategy Using High-Sensitivity Cardiac Troponin I Reduced Length of Stay, Hospital Readmissions in Suspected ACS Patients – American College of Cardiology (free)
Related Studies: Randomized Trial: High-Sensitivity Troponin in the Evaluation of Suspected Acute Coronary Syndrome (free study and commentaries) AND Cohort Study: The Introduction of High-sensitive Troponins Had No Impact on Survival (free study and commentaries)
Related Commentary on Twitter
In an RCT of 31,492 patients with suspected acute coronary syndrome, a rule out pathway using a hs-TnI risk stratification threshold of 5ng/L reduced length of stay by 3.3hrs (57% ⬆️ in ED discharge) with no evidence of harm at one year #ESCCongress #HiSTORIC #troponin pic.twitter.com/5hTUcxAyLF
— Andrew Chapman (@chapdoc1) September 1, 2019
#ESCCongress – [Not Published Yet] Randomized Trial: SGLT2 inhibitors Seems Beneficial for Heart Failure Even in Nondiabetics
2 Sep, 2019 | 01:09h | UTCCommentaries: Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction – DAPA-HF – American College of Cardiology (free) Dapagliflozin reduces death and hospitalisation in patients with heart failure – European Society of Cardiology (free)
Related Commentary on Twitter
DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups.
SGLT2 inhibitors just better diuretics or the "statins of HF"?@escardio #cardiotwitter pic.twitter.com/nzTv58d0cd— Stephan Achenbach (@Steph_Achenbach) September 1, 2019
#ESCCongress – [Abstract Only] Randomized Trial: Angiotensin–Neprilysin Inhibition Not Beneficial for Heart Failure with Preserved Ejection Fraction
2 Sep, 2019 | 01:03h | UTCAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: PARAGON-HF: Sacubitril-Valsartan in HFpEF Patients Did Not Result in Significantly Lower Rates of Hospitalizations, Death – American College of Cardiology (free)
Related Commentary on Twitter
#PARAGON-HF released!#ESCCongress Sacubitril–valsartan did not result in a significantly lower rate of total hospitalizations for heart failure & death from CV causes among patients with heart failure and an ejection fraction of >|=45%
? https://t.co/Q7rwiDyLT4… pic.twitter.com/ktumqXFrO8— Dr. Martha Gulati (@DrMarthaGulati) September 1, 2019
#ESCCongress – Observational Study: A Low High-sensitive Troponin has a Negative Predictive Value of 99.8% for Myocardial Infarction or Cardiac Death Within 30 days in Patients with Suspected Acute Coronary Syndrome and at Least 2 Hours of Symptoms
2 Sep, 2019 | 01:04h | UTC
#ESCCongress – Cohort Study: Cardiovascular Disease Patients May Benefit More from Exercise than Healthy People
2 Sep, 2019 | 00:58h | UTCNews Release: Cardiovascular disease patients benefit more from exercise than healthy people – European Society of Cardiology (free)
#ESCCongress – [Abstract Only] Randomized Trial: Prasugrel Better than Ticagrelor for Patients with Acute Coronary Syndrome with Planned Invasive Evaluation
2 Sep, 2019 | 00:59h | UTCTicagrelor or Prasugrel in Patients with Acute Coronary Syndromes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Prasugrel cuts ischaemic events in acute coronary syndrome patients – European Society of Cardiology (free) AND Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5 – TCTMD (free) AND Intracoronary Stenting and Antithrombotic Regimen 5 – ISAR-REACT 5 – American College of Cardiology (free)
Related Commentary on Twitter
ISAR-REACT 5 presented at #ESCCongress and published in @NEJM:
4000 pats with ACS randomized to Ticagrelor vs Prasugrel:
comp endpoint (death/MI/stroke) 9.3% for Tica, 6.9% for Prasugrel (driven by MI), similar bleeding.well, thats something! https://t.co/JcLkJTRhAw pic.twitter.com/PNxdsM0lik
— Konstantin Krychtiuk (@krychtiukmd) September 1, 2019
#ESCCongress – [Not Published Yet] Randomized Trial: Clopidogrel a Better Option than Ticagrelor or Prasugrel for Elderly Patients with Non-ST-segment Elevation Acute Coronary Syndrome
2 Sep, 2019 | 00:57h | UTCCommentaries: Randomized Comparison of Clopidogrel Versus Ticagrelor or Prasugrel in Patients of 70 years or Older With Non-ST-Elevation Acute Coronary Syndrome – POPular AGE – American College of Cardiology (free) AND POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients – TCTMD (free)
#ESCCongress – [Abstract Only] Randomized Trial: No Overall Benefit from Ticagrelor added to Aspirin in Patients with Stable Coronary Disease and Diabetes
2 Sep, 2019 | 00:56h | UTCTicagrelor in Patients with Stable Coronary Disease and Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Related Study: Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial – The Lancet (free registration required)
Commentaries: THEMIS: No overall benefit of ticagrelor in people with diabetes, coronary artery disease – Medicine Matters (free) AND THEMIS, THEMIS-PCI Assess Benefits of Ticagrelor Plus Aspirin in Patients With Stable CAD and Diabetes, History of PCI – American College of Cardiology (free)
Related Commentary on Twitter
THEMIS: Among patients with stable IHD & type 2 diabetes, ticagrelor+aspirin➡⬇️risk of major adverse ischemic events, but with an ⬆ in major bleeding events compared with the placebo/aspirin group.@escardio #ACC #ESCCongress @DLBHATTMD @iamritu @ErinMichos @AnastasiaSMihai pic.twitter.com/aAeLDEiVsY
— Meghana Prakash (@megnahprakash) September 1, 2019